<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384601</url>
  </required_header>
  <id_info>
    <org_study_id>Dragon III-Phase 3</org_study_id>
    <nct_id>NCT04384601</nct_id>
  </id_info>
  <brief_title>Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer</brief_title>
  <official_title>Efficacy Study of FLOT Versus SOX Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer: A Phase 3 Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an
      investigator initiated; phase 3, open label, multi-center randomized controlled study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non inferiority of SOX will be tested against FLOT. This study will be conducted at multiple
      center of China and will invite international centers to join it.The sponsor of this study is
      Ruijin Hospital and the project is supported by the Shanghai Key Laboratory of Gastric
      Neoplasms and Institute of Digestive Surgery, Shanghai.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour</measure>
    <time_frame>Upto three months</time_frame>
    <description>Tumor regression grade (TRG), Becker criteria Grade 1a :Complete tumor regression: 0% residual tumor per tumor bed Grade 1b: Subtotal tumor regression: &lt;10% residual tumor per tumor bed Grade 2: Partial tumor regression: 10-50% residual tumor per tumor bed Grade 3: Minimal or no tumor regression: &gt;50% residual tumor per tumor bed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Five years</time_frame>
    <description>Overall survival Time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Three years</time_frame>
    <description>Disease free survival Time from randomization to relapse or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>SOX Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three preoperative and three postoperative cycles of SOX chemotherapy
A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)
Repeated every 21st day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLOT Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four preoperative and four postoperative cycles of FLOT chemotherapy
A cycle consist of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous
Repeated every 15th day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Perioperative chemotherapy will be administered according to description in two arms.</description>
    <arm_group_label>FLOT Chemotherapy</arm_group_label>
    <arm_group_label>SOX Chemotherapy</arm_group_label>
    <other_name>FLOT chemotherapy</other_name>
    <other_name>SOX chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology confirmed non-obstructive adenocarcinoma of stomach or esophago-gastric
             junction.

          -  Clinical stage: Clinical Tumor-Node-Metastasis (cTNM:) stage III

          -  Performance status: Eastern Cooperative Oncology Group (ECOG) â‰¤ 2 (normal to
             symptomatic but in bed less than half the day)

          -  Clinically fit for systemic chemotherapy and gastric cancer surgery, i.e. adequate
             renal, hepatic, hematologic and pulmonary function.

          -  Written informed consent

        Exclusion Criteria:

          -  Clinically unfit for systemic chemotherapy and gastric cancer surgery, i.e.
             uncontrolled cardiac disease, or other clinically significant uncontrolled
             comorbidities, unable to undergo general anesthesia

          -  Distant metastases (including retroperitoneal lymph node)

          -  Locally advanced inoperable disease (Clinical assessment)

          -  Relapse of gastric cancer

          -  Malignant secondary disease

          -  Prior chemo or radio therapy

          -  Inclusion in another clinical trial

          -  Known contraindications or hypersensitivity for planned chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birendra K Sah, PH D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen Li, PH D</last_name>
    <role>Study Director</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhenggang Zhu, PH D</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birendra K Sah, Ph D</last_name>
    <phone>0086-13817516354</phone>
    <email>rjsurgeon@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Birendra K Sah, Ph D</last_name>
      <phone>008613817516354</phone>
      <email>rjsurgeon@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>BIRENDRA KUMAR SAH</investigator_full_name>
    <investigator_title>Surgeon</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastric Adenocarcinoma</keyword>
  <keyword>Stomach Cancer, Adenocarcinoma</keyword>
  <keyword>Chemotherapy Effect</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

